Laboratório de Imunologia Celular e Molecular, Departamento de Análises Clínicas e Toxicológicas da Faculdade de Farmácia, Odontologia e Enfermagem, Universidade Federal do Ceará - UFC, Rua Pastor Samuel Munguba, 1210 - Rodolfo Teófilo, Fortaleza, Ceará, Brasil.
Laboratório de Toxinologia Molecular, NUBIMED - Núcleo de Biomedicina, Universidade Federal do Ceará - UFC. Fortaleza, Ceará, Brasil.
Virus Res. 2024 Apr;342:199339. doi: 10.1016/j.virusres.2024.199339. Epub 2024 Feb 22.
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. According to the World Health Organization (WHO), there have been over 760 million reported cases and over 6 million deaths caused by this disease worldwide. The severity of COVID-19 is based on symptoms presented by the patient and is divided as asymptomatic, mild, moderate, severe, and critical. The manifestations are interconnected with genetic variations. The innate immunity is the quickest response mechanism of an organism against viruses. Type I interferon pathway plays a key role in antiviral responses due to viral replication inhibition in infected cells and adaptive immunity stimulation induced by interferon molecules. Thus, variants in type I interferon pathway's genes are being studied in different COVID-19 manifestations. This review summarizes the role of variants in type I interferon pathway's genes on prognosis and severity progression of COVID-19.
新型冠状病毒肺炎(COVID-19)是由 SARS-CoV-2 引起的传染病。根据世界卫生组织(WHO)的数据,全球已报告超过 7.6 亿例病例,超过 600 万人死于该病。COVID-19 的严重程度取决于患者的症状,并分为无症状、轻症、中症、重症和危重症。这些表现与遗传变异有关。固有免疫是机体对抗病毒的最快反应机制。I 型干扰素途径在抗病毒反应中起着关键作用,因为它可以抑制感染细胞中的病毒复制,并通过干扰素分子诱导适应性免疫。因此,I 型干扰素途径基因中的变异体正在不同的 COVID-19 表现中进行研究。本综述总结了 I 型干扰素途径基因变异体对 COVID-19 预后和严重程度进展的作用。